Hematopoietic Stem Cell TransplantationTransplantation, HomologousTransplantation ConditioningGraft vs Host DiseaseHematologic NeoplasmsMyeloablative AgonistsBone Marrow TransplantationBone MarrowWhole-Body IrradiationUnrelated DonorsGraft vs Tumor EffectBone Marrow CellsTransplantation, AutologousTissue DonorsGraft vs Leukemia EffectHistocompatibility TestingVidarabineTransplantation ChimeraTreatment OutcomeLeukemia, Myeloid, AcutePeripheral Blood Stem Cell TransplantationRecurrenceChimerismLeukemiaRetrospective StudiesHistocompatibilityBusulfanMyeloid CellsCord Blood Stem Cell TransplantationSiblingsGraft SurvivalStem Cell TransplantationDonor SelectionMyelodysplastic SyndromesSurvival AnalysisHLA AntigensMinor Histocompatibility AntigensRemission InductionImmunosuppressive AgentsSurvival RateHematologic DiseasesHematopoietic Stem CellsDisease-Free SurvivalBone and BonesAllograftsPrecursor Cell Lymphoblastic Leukemia-LymphomaAcute DiseaseGraft RejectionCyclosporineT-LymphocytesTime FactorsLiver TransplantationLeukemia, Myelogenous, Chronic, BCR-ABL PositiveFollow-Up StudiesCombined Modality TherapyHand Deformities, CongenitalMycophenolic AcidLymphoma, Non-HodgkinCyclophosphamideHematopoiesisRisk FactorsLymphoproliferative DisordersLiving DonorsLymphocyte DepletionLymphomaTacrolimusChronic DiseaseMice, Inbred C57BLSalvage TherapyKidney TransplantationCell TransplantationPrognosisTransplantation ImmunologyAntineoplastic AgentsAge FactorsMultiple MyelomaBone Marrow DiseasesAnemia, AplasticCell DifferentiationCohort StudiesCytomegalovirus InfectionsBone RemodelingCD8-Positive T-LymphocytesBone Marrow ExaminationTransplantationAntigens, CD34Flow CytometryHeart TransplantationBone Marrow NeoplasmsLeukemia, MyeloidMice, Inbred BALB CIncidenceCells, CulturedTransplantation, IsogeneicDirected Tissue DonationProspective StudiesSurvivorsBone Marrow PurgingAntineoplastic Combined Chemotherapy ProtocolsAntilymphocyte Serum